|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ИНХС РАН |
||
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinomaстатья
- Авторы: Abou-Alfa Ghassan K., Lau George, Kudo Masatoshi, Chan Stephen L., Kelley Robin Kate, Furuse Junji, Sukeepaisarnjaroen Wattana, Kang Yoon-Koo, Van Dao Tu, De Toni Enrico N., Rimassa Lorenza, Breder Valeriy, Vasilyev Alexander, Heurgué Alexandra, Tam Vincent C., Mody Kabir, Thungappa Satheesh Chiradoni, Ostapenko Yuriy, Yau Thomas, Azevedo Sergio, Varela María, Cheng Ann-Lii, Qin Shukui, Galle Peter R., Ali Sajid, Marcovitz Michelle, Makowsky Mallory, He Philip, Kurland John F., Negro Alejandra, Sangro Bruno
- Журнал: NEJM Evidence
- Том: 1
- Номер: 8
- Год издания: 2022
- Издательство: NEJM Group
- Местоположение издательства: USA
- DOI: 10.1056/EVIDoa2100070
- Аннотация: This trial examined overall survival (OS) with tremelimumab plus durvalumab, durvalumab alone, or sorafenib in untreated patients with hepatocellular cancer who were not candidates for locoregional therapy. Median OS increased significantly by 2.5 months (16.4 vs. 13.8) with single-dose tremelimumab plus durvalumab treatment every 4 weeks versus sorafenib alone.AB - This trial examined overall survival (OS) with tremelimumab plus durvalumab, durvalumab alone, or sorafenib in untreated patients with hepatocellular cancer who were not candidates for locoregional therapy. Median OS increased significantly by 2.5 months (16.4 vs. 13.8) with single-dose tremelimumab plus durvalumab treatment every 4 weeks versus sorafenib alone
- Добавил в систему: Бредер Валерий Владимирович